Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec.
Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...